In ER + HER2-breast cancers, the Oncotype DX 21 gene assay has been developed and validated for determining the risk of recurrence and potential benefit of adjuvant chemotherapy for an individual patient [31,32]. The gene discussed is ERBB2; the disease is breast carcinoma.